Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

Is Robotic Surgery the Future for Hernia Repair? Not So Fast

Published: Fri, 23 Feb 2018 12:00:00 EST
Robotic-assisted hernia repair is becoming increasingly popular, but the value of this technique remains controversial.
Annals of Surgery

Malignant Hyperthermia in the Post-Genomics Era

Published: Fri, 23 Feb 2018 12:00:00 EST
This review summarizes the latest evidence on the genetics of malignant hyperthermia susceptibility, guidelines for genetic diagnosis, and the limitations of current genetic screening.

Stroke Risk and Estrogen Contraceptives in Women With Migraine

Published: Fri, 23 Feb 2018 12:00:00 EST
Guidelines have recommended avoiding combined hormonal contraceptives in women with migraine with aura due to increased stroke risk. Does current evidence support this, and is the risk dose-related?

Obesity and Sleep Disorders in Postmenopausal Women

Published: Fri, 23 Feb 2018 12:00:00 EST
This study investigated the relationship between obesity and sleep architecture in postmenopausal women.
Displaying results 5-8 (of 20)
 1 - 2 - 3 - 4 - 5 


Santhera offers Raxone to U.S. DMD patients through expanded access program

Published: Thu, 22 Feb 2018 09:36:09 +0000
Santhera has suffered several regulatory setbacks around Raxone (idebenone) in Duchenne muscular dystrophy (DMD). In the absence of official approvals, the company is offering the drug for patients in the U.S. through an expanded access program operated by Clinigen.

GW cannabinoid drug fails midphase epilepsy trial

Published: Thu, 22 Feb 2018 09:14:35 +0000
GW Pharmaceuticals’ GWP42006 has failed to outperform placebo in a phase 2a focal seizure trial. The setback wiped 5% off GW’s stock and dented the prospects of the cannabidivarin candidate.

Arcus Biosciences eyes $100M IPO

Published: Wed, 21 Feb 2018 15:27:01 +0000
Mere months after bagging $107 million in its series C round, Arcus Biosciences is teeing up for a $100 million IPO, which will drive the clinical development of its lead assets into 2020.

Medigene gets OK for first trial of T-cell receptor therapy

Published: Wed, 21 Feb 2018 13:45:56 +0000
Medigene has been given a green light by regulators in Germany to start human trials of MDG1011, the lead candidate to come out of its modified T-cell program.
Displaying results 5-8 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy